227 related articles for article (PubMed ID: 17683996)
21. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.
Cortet B; Hachulla E; Barton I; Bonvoisin B; Roux C
Rev Rhum Engl Ed; 1999 Apr; 66(4):214-9. PubMed ID: 10339777
[TBL] [Abstract][Full Text] [Related]
22. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.
Saarto T; Vehmanen L; Blomqvist C; Elomaa I
J Clin Oncol; 2008 Sep; 26(26):4289-95. PubMed ID: 18779616
[TBL] [Abstract][Full Text] [Related]
23. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
24. Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.
Rymuza J; Popow M; Żurecka Z; Przedlacki J; Bednarczuk T; Miśkiewicz P
Endocrine; 2019 May; 64(2):308-315. PubMed ID: 30506426
[TBL] [Abstract][Full Text] [Related]
25. Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass.
Filipponi P; Cristallini S; Policani G; Schifini MF; Casciari C; Garinei P
Bone; 2000 Mar; 26(3):269-74. PubMed ID: 10710000
[TBL] [Abstract][Full Text] [Related]
26. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
[TBL] [Abstract][Full Text] [Related]
28. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
29. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
[TBL] [Abstract][Full Text] [Related]
30. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
31. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer.
McCloskey E; Paterson A; Kanis J; Tähtelä R; Powles T
Eur J Cancer; 2010 Feb; 46(3):558-65. PubMed ID: 20031392
[TBL] [Abstract][Full Text] [Related]
32. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
33. Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Sánchez-Guerrero J; Fragoso-Loyo HE; Neuwelt CM; Wallace DJ; Ginzler EM; Sherrer YR; McIlwain HH; Freeman PG; Aranow C; Petri MA; Deodhar AA; Blanton E; Manzi S; Kavanaugh A; Lisse JR; Ramsey-Goldman R; McKay JD; Kivitz AJ; Mease PJ; Winkler AE; Kahl LE; Lee AH; Furie RA; Strand CV; Lou L; Ahmed M; Quarles B; Schwartz KE
J Rheumatol; 2008 Aug; 35(8):1567-75. PubMed ID: 18634158
[TBL] [Abstract][Full Text] [Related]
34. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
Emkey R; Delmas PD; Goemaere S; Liberman UA; Poubelle PE; Daifotis AG; Verbruggen N; Lombardi A; Czachur M
Arthritis Rheum; 2003 Apr; 48(4):1102-8. PubMed ID: 12687554
[TBL] [Abstract][Full Text] [Related]
35. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?
van der Goes MC; Jacobs JW; Jurgens MS; Bakker MF; van der Veen MJ; van der Werf JH; Welsing PM; Bijlsma JW
Osteoporos Int; 2013 Apr; 24(4):1429-36. PubMed ID: 23011680
[TBL] [Abstract][Full Text] [Related]
36. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.
Powles TJ; McCloskey E; Paterson AH; Ashley S; Tidy VA; Nevantaus A; Rosenqvist K; Kanis J
J Natl Cancer Inst; 1998 May; 90(9):704-8. PubMed ID: 9586668
[TBL] [Abstract][Full Text] [Related]
37. Bisphosphonates in the treatment of thalassemia-induced osteoporosis.
Morabito N; Lasco A; Gaudio A; Crisafulli A; Di Pietro C; Meo A; Frisina N
Osteoporos Int; 2002 Aug; 13(8):644-9. PubMed ID: 12181623
[TBL] [Abstract][Full Text] [Related]
38. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
Chevrel G; Schott AM; Fontanges E; Charrin JE; Lina-Granade G; Duboeuf F; Garnero P; Arlot M; Raynal C; Meunier PJ
J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
[TBL] [Abstract][Full Text] [Related]
39. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D
Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
[TBL] [Abstract][Full Text] [Related]
40. Calcitriol does not prevent bone loss in patients with asthma receiving corticosteroid therapy: a double-blind placebo-controlled trial.
McDonald CF; Zebaze RM; Seeman E
Osteoporos Int; 2006 Oct; 17(10):1546-51. PubMed ID: 16832714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
